Dilution of Share Value Through Share Acquisition Rights and Capital Increases
First written in FY2024. 3 of 4 entries say "Materialised", first in FY2025-H1. Latest entry: 2026-05-14.
PRISM BioLab moved to the "Worse" side of this theme in 2025, 4 years after the typical company in this theme (2021).
The whole theme swung hardest in 2017: 17 of 34 companies on the "Worse" side.
43 other companies' latest entry also says "Materialised".
- 2026-05-14MaterialisedEarnings
「This was mainly due to increases of ¥8,844 thousand each in share capital and legal capital surplus resulting from the exercise of stock options, among other factors.」
An increase in shares and capital resulting from the exercise of stock options also occurred during the current interim period. - FY2025MaterialisedAnnual report
「1 October 2024–30 September 2025」
During the fiscal year, common shares increased by 855,200 through the exercise of stock acquisition rights. As of the end of the month preceding the filing date, potential shares totaled 3,489,900, or 9.5% of total issued shares, indicating that the dilution risk remains. - FY2025-H1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the interim accounting period, the number of issued shares increased by 716,800 through the exercise of stock acquisition rights. In addition, as a subsequent event, the issuance of stock acquisition rights covering a total of 340,100 shares was approved. - FY2024First statedAnnual report
「The potential shares represented by these stock acquisition rights total 4,291,000 shares, equivalent to 11.9% of the 35,954,800 issued shares.」
The company explains the potential for dilution from future share issuances accompanying the expansion of research and development and from the exercise of stock acquisition rights.